SEC Filing Analysis: Apogee Therapeutics, Inc. (APGE)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The CEO of Apogee Therapeutics sold $1.26 million worth of common stock under a pre-arranged Rule 10b5-1 trading plan.
• Market Impact: The transaction is considered routine and is unlikely to have a material impact on the stock, given its small size relative to the company's market cap and the pre-scheduled nature of the sale.

Company Information

Field	Value
Company	Apogee Therapeutics, Inc.
Ticker Symbol	APGE
CIK	0001974640
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	HENDERSON MICHAEL THOMAS
CIK	0001779990
Title/Position	Chief Executive Officer
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-13
Transaction Code	S (Sale)
Security Type	Common Stock
Shares Involved	20,000
Average Price Per Share	$63.01
Total Value	$1,260,109.70
Shares Owned After	1,272,987
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,260,109.70
% of Market Cap	0.029%
Shares Transacted	20,000
% of Shares Outstanding	0.043%
Post-Transaction Ownership	1,272,987 shares (2.76% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $1.26 million sale is negligible compared to Apogee's $4.31 billion market capitalization, representing only 0.029% of the company's value.
• Ownership Concentration: The sale was minor, reducing the CEO's holdings by only ~1.55%. He retains a significant stake of 2.76% of all outstanding shares post-transaction.
• Transaction Significance: The sale's size is well below thresholds for significance. Both the value as a percentage of market cap (0.029%) and shares as a percentage of outstanding (0.043%) are minimal.

Additional Context

Special Circumstances

• The filing explicitly states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. This indicates the sale was pre-scheduled and not based on any immediate, non-public information, which significantly lowers its informational value to investors.